Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05029778
Other study ID # 097/20
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date October 20, 2021
Est. completion date January 20, 2024

Study information

Verified date August 2021
Source Hospital Civil de Guadalajara
Contact Jorge Bravo Rubio, Dr
Phone 3221186759
Email naranjo125@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Introduction: The high incidence of intrauterine growth restriction is a public health problem; in this pathology, newborns present weight below the 10th percentile, this implies an increase in morbidity in the short term (complications due to hypoxia) and long term (pathologies typical of Fetal Programming) as well as the cost of health services. L-arginine at different doses has been used for some pathologies such as preeclampsia with controversial results. Authors have mentioned that the joint administration of l-citrulline can increase the efficacy of l-arginine. A stunted fetus is a challenge for the fetal physician; due to the complexity of the follow-up, but above all to determine the moment for the termination of the pregnancy. Finding some treatment to promote weight gain would improve the short- and long-term expectations of these infants. General objective To determine the efficacy of L-arginine + L-Citrulline (3 / 2g) every 24 hours, in fetuses with a decrease in their growth curve in the third trimester of pregnancy. Material and methods Clinical trial, parallel, controlled, randomized simple, Double blind. Two groups of pregnant women will be carried out in the third trimester; fetus with a decrease in its growth curve, percentile> 10 and <25 for gestation age, they will be given an informed consent letter and they will be randomized (double blind), they will proceed to give intervention (L-arginine + Citrin (3 / 2 g) every 24 hours Vs placebo), a follow-up will be carried out every two weeks, where the weight and growth curve will be calculated in percentile, until the resolution of the pregnancy and data will be taken from the perinatal results in both groups. Statistic analysis Medics of central tendency will be calculated and Chi squared will be applied for qualitative variables, T of student for qualitative variables and it is considered P <0.005.


Description:

50 patients with a pregnancy of more than 26 weeks of gestation, 25 with intervention and 25 control will be included; in which the fetus is between 10 and 25th percentile . It will be carried out in the obstetric service of the old civil hospital, with a double-blind randomization. Evaluations will be carried out every two weeks where the fetal weight, umbilical artery Doppler, middle cerebral artery, venous duct, uterine arteries, amniotic fluid, placenta will be evaluated. The assessment will be made until birth, from where the birth weight, height, Apgar, Capurro score, characteristics and placental weight, approximate bleeding will be collected.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 41
Est. completion date January 20, 2024
Est. primary completion date October 20, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Pregnancy with a single fetus - Patient over 18 years of age - Patient under 35 years of age - Pregnancy greater than 25 weeks' gestation confirmed by first trimester ultrasound or reliable last period - Fetus with decrease or flattening of its growth curve by ultrasound (P> 10 and <25) - Apparently healthy fetus - Fetus without Doppler alterations in any of its blood vessels (Venous Ductus, Cerebral Artery medial, Umbilical Artery . Exclusion Criteria: - Fetus diagnosed with a malformation - Fetus diagnosed with a syndrome or chromosomopathy - Fetus below the 10th percentile for gestational age by ultrasound - Mother with Type 1, Type 2 or Gestational Diabetes mellitus. - Chronic maternal hypertension - Preeclampsia with data of severity or early onset - Aspirin intake (100-150 mg a day from the first trimester of pregnancy) - Fetus with a poor ultrasonographic window for evaluation. - Mother with BMI <18.5 prior to pregnancy - Maternal BMI> 30 - Known allergy to treatment - Non-reassuring fetal state. - Abnormal placental insertion. - Patient with renal insufficiency, LUPUS or Antiphospholipid syndrome

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
L-arginine 3g + L-Citruline 2 g
receive L-arginine 3g + l-Citruline 2 g PO, for 24 h, until birth.
Drug:
Placebo
receive placebo 3g PO, for 24 h, until birth.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hospital Civil de Guadalajara

References & Publications (11)

Ananth CV, Vintzileos AM. Distinguishing pathological from constitutional small for gestational age births in population-based studies. Early Hum Dev. 2009 Oct;85(10):653-8. doi: 10.1016/j.earlhumdev.2009.09.004. Epub 2009 Sep 27. — View Citation

Barker DJ, Osmond C, Kajantie E, Eriksson JG. Growth and chronic disease: findings in the Helsinki Birth Cohort. Ann Hum Biol. 2009 Sep-Oct;36(5):445-58. doi: 10.1080/03014460902980295. — View Citation

Bourdon A, Parnet P, Nowak C, Tran NT, Winer N, Darmaun D. L-Citrulline Supplementation Enhances Fetal Growth and Protein Synthesis in Rats with Intrauterine Growth Restriction. J Nutr. 2016 Mar;146(3):532-41. doi: 10.3945/jn.115.221267. Epub 2016 Feb 10. — View Citation

Bujold E, Morency AM, Roberge S, Lacasse Y, Forest JC, Giguère Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet G — View Citation

Byrne BM, Howard RB, Morrow RJ, Whiteley KJ, Adamson SL. Role of the L-arginine nitric oxide pathway in hypoxic fetoplacental vasoconstriction. Placenta. 1997 Nov;18(8):627-34. — View Citation

Camarena Pulido EE, García Benavides L, Panduro Barón JG, Pascoe Gonzalez S, Madrigal Saray AJ, García Padilla FE, Totsuka Sutto SE. Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: A double-blind, randomized, clinical trial. H — View Citation

Chen J, Gong X, Chen P, Luo K, Zhang X. Effect of L-arginine and sildenafil citrate on intrauterine growth restriction fetuses: a meta-analysis. BMC Pregnancy Childbirth. 2016 Aug 16;16:225. doi: 10.1186/s12884-016-1009-6. Review. — View Citation

Colella M, Frérot A, Novais ARB, Baud O. Neonatal and Long-Term Consequences of Fetal Growth Restriction. Curr Pediatr Rev. 2018;14(4):212-218. doi: 10.2174/1573396314666180712114531. Review. — View Citation

Cottrell E, Tropea T, Ormesher L, Greenwood S, Wareing M, Johnstone E, Myers J, Sibley C. Dietary interventions for fetal growth restriction - therapeutic potential of dietary nitrate supplementation in pregnancy. J Physiol. 2017 Aug 1;595(15):5095-5102. — View Citation

Crispi F, Miranda J, Gratacós E. Long-term cardiovascular consequences of fetal growth restriction: biology, clinical implications, and opportunities for prevention of adult disease. Am J Obstet Gynecol. 2018 Feb;218(2S):S869-S879. doi: 10.1016/j.ajog.201 — View Citation

Dover GJ. The Barker hypothesis: how pediatricans will diagnose and prevent common adult-onset diseases. Trans Am Clin Climatol Assoc. 2009;120:199-207. Review. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Fetal Growth fetal weight gain 10 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT04502823 - Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler N/A
Not yet recruiting NCT03625518 - Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes Early Phase 1
Completed NCT05176041 - SLE Therapy Changes in Pregnancy and Relation to Pregnancy Outcome
Completed NCT02379728 - Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth N/A
Completed NCT01695070 - Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies Phase 4
Completed NCT01352234 - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia Phase 4
Not yet recruiting NCT05284474 - Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler N/A
Completed NCT04289350 - Day to Day Variation in Fetal Heart Rate Variability
Recruiting NCT03662178 - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Recruiting NCT05023161 - Non-invasive Placental Chromosome Exploration of Intrauterine Growth Restriction
Completed NCT02590536 - A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction Phase 3
Recruiting NCT05576207 - BEP Supplementation Research in Bangladesh (JiVitA-BEP-IR) N/A
Active, not recruiting NCT05160649 - Effect of Covid 19 Infection on Fetomaternal Outcome
Completed NCT02280031 - Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial. Phase 2
Recruiting NCT04389099 - MRI Angiography of Physiological and Pathological Pregnancy Placentas Ex-vivo
Recruiting NCT06039319 - Acute Effects of Maternal Exercise and the Growth Restricted Pregnancy
Recruiting NCT05651347 - Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction Phase 3
Recruiting NCT02336243 - A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders Phase 3
Active, not recruiting NCT01594463 - Routine Ultrasound Screening in the Third Trimester N/A